RENBP and neoplasm: Because the concentration of shed MSLN is ~300 nM in the ECS of a tumor of 300 mm3, 89Zr-amatuximab (53.6 nM) in the ECS would mostly exist as an antibody-Ag complex distributed throughout the entire tumor, presumably bypassing the binding sites on the surface of tumor cells nearest to the vasculature.